Search results
Showing 1601 to 1650 of 3030 results for all
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
In development Reference number: GID-TA11091 Expected publication date: 04 June 2026
In development Reference number: GID-TA11566 Expected publication date: TBC
In development Reference number: GID-TA11416 Expected publication date: 22 October 2026
In development Reference number: GID-TA10979 Expected publication date: TBC
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)
Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.
Neuropad for detecting preclinical diabetic peripheral neuropathy (HTG486)
Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy.
Modular updates for our technology appraisal guidance On this page, you'll find all our modular updates relating to our technology...
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making
Evidence-based recommendations on percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia. This involves using heat to destroy selected areas of the heart to prevent the occurrence or conduction of abnormal electrical activity.
View recommendations for HTG187Show all sections
Sections for HTG187
This indicator covers the proportion of women aged 53 to 70 years whose record shows a breast screening test has been performed within the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG84
Subscribe to our GP reference panel and contribute to the development of NICE guidance in a quick and easy way.
Radiation dose monitoring software for medical imaging with ionising radiation (MIB127)
NICE has developed a medtech innovation briefing (MIB) on radiation dose monitoring software for medical imaging with ionising radiation .
Thopaz+ portable digital system for managing chest drains (HTG465)
Evidence-based recommendations on Thopaz+ for managing chest drains.
Asthma. Patient decision aid on asthma inhalers and climate change (BTS, NICE, SIGN)
doses you have left. There are lots of types of dry powder inhaler and not all are shown here. No Soft mist inhalers (SMIs) You press a...
The geko device for reducing the risk of venous thromboembolism (HTG344)
Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer in adults.
This quality standard covers the initial management of self-harm and the provision of longer-term support for children and young people (aged 8 to 18) and adults (aged 18 and over) who self-harm. It describes high-quality care in priority areas for improvement.
View quality statements for QS34Show all sections
Sections for QS34
- Quality statements
- Quality statement 1: Compassion, respect and dignity
- Quality statement 2: Initial assessments
- Quality statement 3: Psychosocial assessments
- Quality statement 4: Observation
- Quality statement 5: Safe physical environments
- Quality statement 6: Care plans
- Quality statement 7: Psychological interventions
This quality standard covers the identification and management of familial and genetic risk and the recognition and management of ovarian, fallopian tube and primary peritoneal cancer or borderline ovarian cancer in women, trans men and non-binary people aged 18 and over with female reproductive organs (ovaries, fallopian tubes or a uterus). It describes high-quality care in priority areas for improvement.
View quality statements for QS18Show all sections
Sections for QS18
- Quality statements
- Quality statement 1: Discussion about risk-reducing surgery
- Quality statement 2: CA125 blood test – age-specific thresholds
- Quality statement 3: Panel germline genetic testing for non-mucinous high-grade epithelial ovarian cancer
- Quality statement 4: Tumour genetic testing for stage 3 or 4 non-mucinous high-grade epithelial ovarian cancer
- Quality statement 5: Treatment of high-risk stage 1 or stage 2 to 4 ovarian cancer
- Update information
- About this quality standard
NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200)
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin for treating chronic hepatitis C in adults.
Digital technologies to support self-management of asthma: early-use assessment (HTG778)
Evidence-based recommendations on the early use of digital technologies to support self-management of asthma.
TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum (MIB134)
NICE has developed a medtech innovation briefing (MIB) on the TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum .
Evidence-based recommendations on botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. This involves injecting botulinum toxin type A into the urethral sphincter.
View recommendations for HTG685Show all sections
GreenLight XPS for treating benign prostatic hyperplasia (HTG650)
Evidence-based recommendations on GreenLight XPS for treating benign prostatic hyperplasia.
Path Finder for freezing of gait in people with Parkinson's disease (MIB170)
NICE has developed a medtech innovation briefing (MIB) on Path Finder for freezing of gait in people with Parkinson’s disease .
In development Reference number: GID-TA11613 Expected publication date: TBC
In development Reference number: GID-TA11649 Expected publication date: 14 October 2026
Ambu aScope 4 RhinoLaryngo for visualising upper airways during rhinolaryngoscopy (MIB316)
NICE has developed a medtech innovation briefing (MIB) on Ambu aScope 4 RhinoLaryngo for visualising upper airways during rhinolaryngoscopy .
Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)
Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.
Brentuximab vedotin in combination for untreated advanced classical Hodgkin lymphoma [ID6437]
In development Reference number: GID-TA11516 Expected publication date: 06 May 2027
Evidence-based recommendations on Kurin Lock for blood culture collection.
Extracorporeal membrane oxygenation for severe acute respiratory failure in adults (HTG260)
Evidence-based recommendations on extracorporeal membrane oxygenation for severe acute respiratory failure in adults. This involves using a tube to carry blood from the right side of the heart and then pump it through an artificial lung where it picks up oxygen.
View recommendations for HTG260Show all sections
Sections for HTG260
Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices (HTG251)
Evidence-based recommendations on percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices. This involves using a special cutting device to remove excess debris inside diseased blood vessels.
View recommendations for HTG251Show all sections
Sections for HTG251
Living-donor lung transplantation for end-stage lung disease (HTG111)
Evidence-based recommendations on living-donor lung transplantation for end-stage lung disease. This involves removing a lung from each of the two donors and replacing the recipient's lungs with the donor lungs.
View recommendations for HTG111Show all sections
In a virtual ward setting, you make assessments at home to support clinical decision-making. Our guidance can help you give advice by highlighting areas to consider and standards of care.
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)
Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Evidence-based recommendations on ramucirumab (Cyramza) for locally advanced or metastatic non-small-cell lung cancer in adults who have had platinum-based chemotherapy.
Find out which guidance and quality standards are awaiting development
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.
Bortezomib monotherapy for relapsed multiple myeloma (TA129)
Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults.
Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)
Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.
Osteoporosis: bone sparing agents (75 years and over) (IND92)
This indicator covers the percentage of patients aged 75 or over with a fragility fracture on or after 1 April 2012, who are currently treated with an appropriate bone-sparing agent. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM31
This indicator covers the percentage of patients aged 50 or over and who have not attained the age of 75, with a record of a fragility fracture on or after 1 April 2012, in whom osteoporosis is confirmed on DXA scan, who are currently treated with an appropriate bone-sparing agent. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM30
Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.
Show all sections
Pegzilarginase for treating arginase-1 deficiency in people 2 years and over (HST35)
Evidence-based recommendations on pegzilarginase (Loargys) for treating arginase-1 deficiency in people 2 years and over.
Show all sections
NICE has developed a medtech innovation briefing (MIB) on Helge for detecting haemolysis .
NICE has developed a medtech innovation briefing (MIB) on RenalSense Clarity RMS for acute kidney injury .